TISSIUM Secures €60 Million in Financing

TISSIUM has announced a €60 million financing package, combining a completed €30 million Series D2 financing with a €30 million financing facility from the European Investment Bank (EIB).

The financing follows a transformational stage for TISSIUM, marked by the U.S. Food and Drug Administration (FDA) marketing authorization of COAPTIUM CONNECT, the company’s first commercial product, its commercial entry into the U.S. market, and continued progress across its pipeline of products addressing unmet needs in atraumatic nerve repair, atraumatic hernia repair, and cardiovascular applications.

The €30 million Series D2 financing was completed at the end of 2025 with broad participation from leading new and existing international investors, including those in the United States. The financing further strengthens TISSIUM’s shareholder base and provides capital to support the company’s commercial and clinical activities as well as its pipeline development and platform expansion.

In addition, TISSIUM secured a financing facility of up to €30 million from the European Investment Bank, aligning with the objectives of InvestEU, which aims to support research, innovation and the development of transformative healthcare technologies across Europe. The facility is available in three €10 million tranches linked to commercial, clinical and financing milestones, mixing dilutive and venture debt financing. TISSIUM drew the first €10 million tranche before the end of June.

The combined financing package provides TISSIUM with significant strategic flexibility as it executes on the U.S. commercial rollout of COAPTIUM CONNECT, advances multiple clinical programs across its various surgical applications, and extends its proprietary biomorphic polymer platform.

“This financing marks an important milestone in TISSIUM’s evolution. Following the FDA marketing authorization of COAPTIUM CONNECT, we are now executing on our transition into a commercial-stage medtech company while continuing to advance a differentiated pipeline built on the same underlying biomorphic polymer platform,” TISSIUM Co-Founder/CEO Christophe Bancel said. “The support of both international investors and the European Investment Bank reflects confidence in our technology, our strategy and our ability to bring meaningful innovation to patients. This financing provides the capital and strategic flexibility required to accelerate commercial execution while continuing to invest in the future growth of our platform.”

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. The company has developed a fully integrated innovation, design, commercialization, and manufacturing platform to support its internal programs as well as co-development partnerships with medtech industry leaders.